Division of General Internal Medicine, Massachusetts General Hospital, Boston, MA, United States; Mongan Institute, Clinical Translational Epidemiology Unit, Massachusetts General Hospital, Boston, MA, United States.
Division of Biostatistics, Massachusetts General Hospital, Boston, MA, United States.
Prev Med. 2021 Oct;151:106640. doi: 10.1016/j.ypmed.2021.106640. Epub 2021 Jun 30.
Cancer screening rates declined sharply early in the COVID-19 pandemic. The impact of the pandemic may have exacerbated existing disparities in cancer screening due to the disproportionate burden of illness and job loss among racial/ ethnic minorities, and potentially, uneven resumption of care between different racial/ ethnic groups. Using electronic health record data from Mass General Brigham (MGB), we assessed changes in rates of breast, cervical, colorectal and lung cancer screening before and during the pandemic. Among patients who received primary care in an MGB-affiliated primary care practice, cancer screening rates were calculated as the number of individuals who received a screening test for each cancer type over the number of individuals due for each test, during each month between April 2019-November 2020. We conducted an interrupted time-series analysis to test for changes in screening rates by race/ethnicity before and during the pandemic. Prior to the pandemic, relative to White individuals, Asian women were less likely to receive breast cancer screening (p < 0.001), and Latinx and Black individuals were less likely to screen for lung cancer (p < 0.001 and p = 0.02). Our results did not show significant improvement or worsening of racial/ethnic disparities for any cancer screening type as screening resumed. However, as of November 2020 rates of screening for breast cancer were lower than pre-pandemic levels for Latinx individuals, and lung cancer screening rates were higher than baseline for Latinx, Black or White individuals. Further monitoring of disparities in cancer screening is warranted as the pandemic evolves.
癌症筛查率在 COVID-19 大流行早期急剧下降。由于少数族裔在疾病负担和失业方面的不成比例,以及不同种族/族裔之间护理恢复情况的不均衡,大流行可能加剧了癌症筛查方面已经存在的差距。利用来自马萨诸塞州综合医院 (MGB) 的电子健康记录数据,我们评估了大流行前后乳腺癌、宫颈癌、结直肠癌和肺癌筛查率的变化。在 MGB 附属初级保健实践中接受初级保健的患者中,癌症筛查率计算为在每个月期间接受每种癌症类型筛查测试的个体数除以应接受每种测试的个体数,时间范围为 2019 年 4 月至 2020 年 11 月。我们进行了中断时间序列分析,以测试大流行前后种族/族裔的筛查率变化。在大流行之前,与白人个体相比,亚洲女性接受乳腺癌筛查的可能性较小(p<0.001),拉丁裔和非裔个体接受肺癌筛查的可能性较小(p<0.001 和 p=0.02)。我们的结果没有显示出任何癌症筛查类型的种族/族裔差异在恢复筛查后有所改善或恶化。然而,截至 2020 年 11 月,拉丁裔个体的乳腺癌筛查率低于大流行前水平,而拉丁裔、非裔或白人个体的肺癌筛查率高于基线。随着大流行的发展,有必要进一步监测癌症筛查方面的差异。